Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal

British Journal of Pharmacology

Volumn 164, Issue 2 B, 2011, Pages 406-418

  Sohn, Yang Sung ^a   Mitterstiller, Anna Maria ^b   Breuer, William ^a   Weiss, Guenter ^b   Cabantchik, Z Ioav ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

anaemia; chelators; infection; iron; macrophages; oxidative stress

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRIC AMMONIUM CITRATE; FERRIC HYDROXIDE SUCROSE; FERROPORTIN; HEPCIDIN; IRON; TRANSFERRIN;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; CELL AGING; CELL DAMAGE; CELL LEVEL; CELLULAR DISTRIBUTION; COCULTURE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG SCREENING; ERYTHROCYTE; ERYTHROPHAGOCYTOSIS; EXPERIMENTAL MODEL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IRON OVERLOAD; IRON STORAGE; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANEMIA, IRON-DEFICIENCY; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL TRANSPORT; CATION TRANSPORT PROTEINS; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOCYTOSIS; ERYTHROCYTES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; K562 CELLS; MACROPHAGES; MICE; OXIDATIVE STRESS; PYRIDONES; TRANSFERRIN; TUMOR CELLS, CULTURED;

EID: 80052243548     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01120.x     Document Type: Article

References (44)

1. Aderem A, Underhill DM, (1999). Mechanisms of phagocytosis in macrophages. Ann Rev Immunol 17: 593-623. (Pubitemid 29241135)
2. Agarwal N, Prchal JT, (2009). Anemia of chronic disease (anemia of inflammation). Acta Haematol 122: 103-108.
3. Babitt JL, Lin HY, (2010). Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD. Am J Kidney Dis 55: 726-741.
4. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY, (2007). Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117: 1933-1939. (Pubitemid 47036327)
5. Beaumont C, Delaby C, (2009). Recycling iron in normal and pathological states. Semin Hematol 46: 328-338.
6. Besarab A, Hörl WH, Silverberg D, (2009). Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome. Oncologist 14 (Suppl. 1): 22-33.
7. Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, Brunelle F, et al,. (2007). Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110: 401-408. (Pubitemid 47026862)
8. Breuer W, Cabantchik ZI, (2009). Disorders affecting iron distribution: causes, consequences and possible treatments. BloodMed.
9. Breuer W, Ermers MJ, Pootrakul P, Abramov A, Hershko C, Cabantchik ZI, (2001). Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 97: 792-798. (Pubitemid 32113415)
10. De Domenico I, Ward DM, Kaplan J, (2009). Specific iron chelators determine the route of ferritin degradation. Blood 114: 4546-4551.
11. Evans RW, Sharma M, Ogwang W, Patel KJ, Bartlett AN, Kontoghiorghes GJ, (1992). The effect of alphaketohydroxypyridine chelators on transferrin saturation in vitro and in vivo. Drugs Today (Barc) 28: 19-23. (Pubitemid 23038082)
12. Finberg KE, (2009). Iron-refractory iron deficiency anemia. Semin Hematol 46: 378-386.
13. Germann UA, (1997). Detection of expressed recombinant protein based on multidrug resistance: P-glycoprotein. Methods Mol Biol 63: 139-159.
14. Glickstein H, Ben El R, Shvartsman M, Cabantchik ZI, (1994). Intracellular labile iron pools as direct targets of iron chelators. A fluorescence study of chelator action in living cells. Blood 106: 3242-3250.
15. Glickstein H, Ben El R, Link G, Breuer W, Konijn AM, Hershko C, et al,. (2006). Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108: 3195-3203.
16. Hider RC, Porter JB, Singh S, (1994). The design of therapeutically useful iron chelators. In:, Bergeron RJ, Brittenham GM, (eds). The Development of Iron Chelators for Clinical Use. CRC Press: Boca Raton, FL, pp. 353-358.
17. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Cortopassi G, Munnich A, et al,. (2008). Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Blood 112: 5219-5227.
18. Kakhlon O, Breuer W, Munnich A, Cabantchik ZI, (2010). Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Can J Physiol Pharmacol 88: 187-196. (invited review).
19. Kalinowski DS, Richardson DR, (2005). The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57: 547-583. (Pubitemid 43036441)
20. Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T, (2007). Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman's disease. Haematologica 92: 857-858. (Pubitemid 350155317)
21. Kemma EHJM, Tjalsma H, Willems HL, Swinkels DW, (2009). Hepcidin: from discovery to differential diagnosis. Hematologica 93: 90-97. doi:10.3324/haematol. 11705. (Pubitemid 351156156)
22. Konijn AM, Glickstein H, Vaisman B, Meyron-Holtz EG, Slotki IN, Cabantchik ZI, (1999). Thecellular labile iron pool and intracellular ferritin in K562 cells. Blood 94: 2128-2134. (Pubitemid 29430430)
23. Lescoat G, Chantrel-Groussard K, Pasdeloup N, Nick H, Brissot P, Gaboriau F, (2007). Antiproliferative and apoptotic effects in rat and human hepatoma cell cultures of the orally active iron chelator ICL670 compared to CP20: a possible relationship with polyamine metabolism. Cell Prolif 40: 755-767. (Pubitemid 47416557)
24. Ludwiczek S, Aigner E, Theurl I, Weiss G, (2003). Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 101: 4148-4154. (Pubitemid 36857898)
25. Macdougall IC, (2010). Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous? Curr Med Res Opin 26: 473-482.
26. Mair SM, Weiss G, (2009). New pharmacological concepts for the treatment of iron overload disorders. Curr Med Chem 16: 576-590.
27. Nairz M, Theurl I, Ludwiczek S, Theurl M, Mair SM, Fritsche G, et al,. (2007). The co-ordinated regulation of iron homeostasis in murine macrophages limits the availability of iron for intracellular Salmonella typhimurium. Cell Microbiol 9: 2126-2140. (Pubitemid 47250286)
28. Nairz M, Theurl I, Schroll A, Theurl M, Fritsche G, Lindner E, et al,. (2009). Absence of functional Hfe protects mice from invasive Salmonella enterica serovar Typhimurium infection via induction of lipocalin-2. Blood 114: 3642-5131.
29. Nemeth E, (2010). Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010: 750643.
30. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al,. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093. (Pubitemid 40007660)
31. Paradkar PN, De Domenico I, Durchfort N, Zohn I, Kaplan J, Ward DM, (2008). Iron depletion limits intracellular bacterial growth in macrophages. Blood 112: 866-874.
32. Recalcati S, Minotti G, Cairo G, (2010). Iron regulatory proteins: from molecular mechanisms to drug development. Antioxid Redox Signal 13: 1593-1616.
33. Reznick AZ, Packer L, (1994). Oxidative damage to proteins: spectrophotometric method for carbonyl assay. Methods Enzymol 223: 357-363.
34. Sasu BJ, Hainu M, Boone TC, Cooke KS, Arvedson TL, Plewa C, et al,. (2010). Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 115: 3616-3624.
35. Schaible U, Kaufman SH, (2004). Iron and microbial infection. Nat Rev Microbiol 2: 946-953. (Pubitemid 39562533)
36. Sohn YS, Breuer W, Munnich A, Cabantchik ZI, (2008). Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications. Blood 113: 1690-1699. (Pubitemid 351213461)
37. Theurl I, Aigner E, Theurl M, Nairz M, Seifert M, Schroll A, et al,. (2009). Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications. Blood 113: 5277-5286.
38. Velasco-Sánchez D, Aracil A, Montero R, Mas A, Jiménez L, O'Callaghan M, et al,. (2011). Combined therapy with idebenone and deferiprone in patients with Friedreich ataxia. Cerebellum 10: 1-8.
39. Voigt W, (2005). Sulforhodamine B assay and chemosensitivity. Methods Mol Med 110: 9-48.
40. Vreugdenhil G, Swaak AJ, de Jeu-Jaspers C, van Eijk HG, (1990). Correlation of iron exchange between the oral iron chelator 1,2-dimethyl-3- hydroxypyrid-4-one(L1) and transferrin and possible antianaemic effects of L1 in rheumatoid arthritis. Ann Rheum Dis 49: 956-957. (Pubitemid 20360774)
41. Weiss G, Goodnough T, (2005). Anemia of chronic disease. New Engl J Med 352: 1011-1023.
42. Yang F, Liu XB, Quinones M, Melby PC, Ghio A, Haile DJ, (2002). Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation. J Biol Chem 277: 39786-39791. (Pubitemid 35190962)
43. Yu PB, Hong CC, Sachidanandan C, (2008). Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33-41. (Pubitemid 350273653)
44. Zhu H, Bunn HF, (1999). Oxygen sensing and signaling: impact on the regulation of physiologically important genes. Respir Physiol 115: 239-247. (Pubitemid 29206488)